AUS
NZ
UK
CA
USA
IND
Key Points:
- Faron Pharmaceuticals will host a Capital Markets Day on October 22, 2024, featuring key presentations from leading experts.
- The agenda includes discussions on the company’s strategy, updated clinical data for bexmarilimab, and market assessments in the MDS space.
- CEO Juho Jalkanen will outline Faron's development plans, while the event also introduces a new Scientific Advisory Board to enhance research efforts.
Faron Pharmaceuticals Ltd. (LSE:FARN, First North: FARON), a clinical-stage biopharmaceutical company dedicated to advancing cancer treatments through innovative immunotherapies, has announced its upcoming Capital Markets Day. This event will take place on Tuesday, October 22, 2024. It aims to engage investors, analysts, and media representatives in a comprehensive discussion about the company’s strategic vision and clinical developments.
The event will feature a lineup of distinguished speakers, including Dr. Mika Kontro, MD, PhD, an Associate Professor at the University of Helsinki; Mr. Ralph Hughes, MSc, BSc, Senior Vice President at PharmaVentures; and key members of Faron's senior management team. Their presentations will cover various aspects of the company's focus and research initiatives, particularly relating to its lead product candidate, bexmarilimab.
The agenda for the Capital Markets Day includes the following key topics:
- Opening Remarks: An introduction to the event and its significance.
- Faron's Strategy and Key Focus Areas: Presented by Dr. Juho Jalkanen, MD, PhD, CEO of Faron Pharmaceuticals, outlining the company’s vision and priorities for future growth.
- BEXMAB Clinical Data: Dr. Mika Kontro will share updated survival data from the ongoing Phase I/II trial of bexmarilimab, providing insights into its efficacy.
- BEXMAB MDS Market Assessment: Mr. Ralph Hughes will present findings from recent market research conducted on myelodysplastic syndromes (MDS), highlighting opportunities for bexmarilimab.
- Faron's Development Plan for Solid Tumors: Dr. Petri Bono, MD, PhD, Chief Medical Officer, will discuss the company's roadmap for developing treatments for solid tumors and the potential of bexmarilimab as a first-in-class immune-oncological therapy.
- Who Benefits from Bexmarilimab and Why: Dr. Maija Hollmén, PhD, Chief Scientific Officer, will explore the future addressable markets for bexmarilimab, outlining who stands to benefit from this novel treatment.
- Q&A Session: An opportunity for attendees to engage directly with the speakers and seek clarifications on discussed topics.
- Closing Remarks: A summary of the key takeaways from the event.
During the event, CEO Juho Jalkanen will provide a detailed overview of Faron’s strategic objectives and the essential areas of focus for the years ahead. Dr. Kontro will offer valuable updates on survival data from the BEXMAB trial, a crucial aspect of Faron's clinical efforts. Mr. Hughes will shed light on the findings of the recent market assessment related to MDS, while Dr. Bono will elaborate on the company’s development plans for solid tumors, emphasizing bexmarilimab’s potential as a pioneering immune-oncological treatment. Additionally, Dr. Hollmén will highlight the market opportunities for bexmarilimab and discuss the formation of the company’s new Scientific Advisory Board (SAB).
This Capital Markets Day represents a significant opportunity for stakeholders to gain insights into Faron Pharmaceuticals' advancements and future direction in the field of cancer treatment.
